1. Home
  2. CRGY vs LQDA Comparison

CRGY vs LQDA Comparison

Compare CRGY & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGY
  • LQDA
  • Stock Information
  • Founded
  • CRGY 1986
  • LQDA 2004
  • Country
  • CRGY United States
  • LQDA United States
  • Employees
  • CRGY N/A
  • LQDA N/A
  • Industry
  • CRGY Oil & Gas Production
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRGY Energy
  • LQDA Health Care
  • Exchange
  • CRGY Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • CRGY 2.0B
  • LQDA 1.9B
  • IPO Year
  • CRGY N/A
  • LQDA 2018
  • Fundamental
  • Price
  • CRGY $8.45
  • LQDA $22.94
  • Analyst Decision
  • CRGY Buy
  • LQDA Strong Buy
  • Analyst Count
  • CRGY 11
  • LQDA 9
  • Target Price
  • CRGY $14.78
  • LQDA $32.67
  • AVG Volume (30 Days)
  • CRGY 4.4M
  • LQDA 2.3M
  • Earning Date
  • CRGY 11-03-2025
  • LQDA 11-12-2025
  • Dividend Yield
  • CRGY 5.73%
  • LQDA N/A
  • EPS Growth
  • CRGY N/A
  • LQDA N/A
  • EPS
  • CRGY 0.12
  • LQDA N/A
  • Revenue
  • CRGY $3,468,319,000.00
  • LQDA $19,322,000.00
  • Revenue This Year
  • CRGY $29.58
  • LQDA $424.31
  • Revenue Next Year
  • CRGY $29.83
  • LQDA $359.32
  • P/E Ratio
  • CRGY $71.86
  • LQDA N/A
  • Revenue Growth
  • CRGY 32.84
  • LQDA 30.20
  • 52 Week Low
  • CRGY $6.83
  • LQDA $9.71
  • 52 Week High
  • CRGY $16.94
  • LQDA $29.94
  • Technical
  • Relative Strength Index (RSI)
  • CRGY 47.06
  • LQDA 47.66
  • Support Level
  • CRGY $8.38
  • LQDA $21.97
  • Resistance Level
  • CRGY $8.68
  • LQDA $24.85
  • Average True Range (ATR)
  • CRGY 0.36
  • LQDA 1.20
  • MACD
  • CRGY -0.00
  • LQDA -0.01
  • Stochastic Oscillator
  • CRGY 34.89
  • LQDA 30.79

About CRGY Crescent Energy Company

Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: